M&A DealNews: DZ BANK advises shareholders of CNP Group
DZ BANK Corporate Finance advised the CNP Group on the sale of 100% of its shares to financial investor capiton, thereby facilitating a succession arrangement for the two shareholders. The CNP Group, which in Germany primarily operates as MIP Pharma, is a pan-European generics manufacturer with a strong presence in Eastern Europe and a broad registration portfolio with a focus on antibiotics, particularly in the field of clindamycins and cephalosporins. The CNP Group has production sites in St. Ingbert-Rohrbach and Homburg and currently employs around 250 people. capiton will make extensive investments at both production sites. The transaction was initiated by Bank 1 Saar.
My biggest thanks go to DZ BANK for their constant support over the past months and the highly professional advice during the sales process. DZ BANK's solution-oriented advice on various complex issues in a market environment influenced by COVID-19 was certainly the key to the successful completion of the transaction.
